In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica DIHEXA PEPTIDE 10MG VIAL UMBRELLA Labs